The Phase Ia trial is designed to assess the safety and efficacy of the company’s drug designed to target chemicals thought to be a cause of Alzheimer’s disease.

Topline results from a phase 2b/3 clinical trial of blarcamesine for individuals with early-stage Alzheimer’s disease showed ...

Delray Medical Center cut the ribbon on its newest high-tech machine that targets brain areas to treat movement disorders ...

Passage Bio’s workforce reduction could affect about 32 people, leaving the company with 26 employees as it continues ...

The Florey Dementia Index (FDI) is valid for predicting the age of onset of mild cognitive impairment (MCI) and Alzhei ...

Groundbreaking research reveals potential link between cytomegalovirus (CMV) and Alzheimer's disease, offering new insights ...

For many years, platinum-based chemotherapy has been one of the mainstays for advanced testicular cancer. Painful peripheral ...

IGC Pharma, Inc (NYSE American:IGC) (”IGC” or the “Company”), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi ...

Having depression is known to increase a person’s risk of developing dementia, but depression is also an early indicator of ...

Jupiter, Florida, Jan. 13, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, ...

Mild chronic small vessel disease, or cerebral small vessel disease (CSVD), is an umbrella term for a range of conditions ...

NDA submitted to U.S. FDA for CAPLYTA® as adjunctive treatment for major depressive disorder; if approved, CAPLYTA® has ...